Portfolio company
Crossfire Oncology
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This company develops kinase-targeting inhibitors, degraders and degrader-antibody conjugates to treat cancer patients.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Kinnate Biopharma
The company develops small molecule kinase inhibitors for patients with difficult-to-treat cancers featuring specific genetic alterations.
KyDo Therapeutics
This company develops covalent-allosteric small molecule inhibitors for the treatment of challenging cancer variants within the oncology sector.
Amphista Therapeutics
This company develops targeted protein degradation medicines to treat patients with cancer and other diseases.
Biotheryx
The company develops protein degrader medicines for patients with cancer and inflammatory diseases.
Scorpion Therapeutics
This clinical-stage company develops small-molecule drugs and targeted therapies for patients with various forms of cancer.
CrossBridge Bio
This company develops dual-payload antibody-drug conjugates to treat solid tumors for healthcare providers and pharmaceutical partners.
ProteoValent Therapeutics
This company develops targeted protein degrader therapies for cancer and haematology patients.
Chromacure
This company develops small molecule therapeutics for oncology patients to address unmet clinical needs in cancer treatment.